BIAF RSI Chart
Last 7 days
12%
Last 30 days
-23.0%
Last 90 days
47.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 4.9M | 0 | 0 | 0 |
2023 | 636.7K | 1.3M | 1.9M | 2.5M |
2022 | 0 | 0 | 0 | 4.8K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 08, 2024 | zannes maria | sold (taxes) | -74,899 | 2.65 | -28,264 | president & ceo |
Apr 08, 2024 | zannes maria | acquired | 75,223 | 1.16 | 64,848 | president & ceo |
Apr 04, 2024 | zannes timothy p | acquired | 75,223 | 1.16 | 64,848 | secretary, evp, gen. counsel |
Apr 04, 2024 | zannes timothy p | sold (taxes) | -74,900 | 2.58 | -29,031 | secretary, evp, gen. counsel |
Apr 03, 2024 | girgenti steven | acquired | 75,223 | 1.16 | 64,848 | - |
Apr 03, 2024 | girgenti steven | sold (taxes) | -74,901 | 2.24 | -33,438 | - |
Feb 26, 2024 | anderson robert a. | acquired | 74,899 | 1.155 | 64,848 | - |
Feb 16, 2024 | girgenti steven | acquired | 60,000 | 1.52 | 39,474 | executive chairman |
Jan 31, 2024 | zannes maria | acquired | - | - | 23,885 | president, ceo |
Jan 31, 2024 | girgenti steven | acquired | - | - | 11,943 | executive chairman |
Which funds bought or sold BIAF recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | 9,328 | 35,552 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -8.00 | - | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | unchanged | - | 138,653 | 156,204 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 13.04 | 2,405 | 6,761 | -% |
May 15, 2024 | CAPTRUST FINANCIAL ADVISORS | reduced | -30.09 | -2,323 | 56,328 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -31,825 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -0.82 | 16,178 | 18,860 | -% |
May 14, 2024 | NORTHERN TRUST CORP | new | - | 27,597 | 27,597 | -% |
May 14, 2024 | Qube Research & Technologies Ltd | unchanged | - | 20.00 | 77.00 | -% |
May 14, 2024 | Sheaff Brock Investment Advisors, LLC | new | - | 20,200 | 20,200 | -% |
Peers (Alternatives to bioAffinity Technologies, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 196.9B | 23.7B | 44.73 | 8.29 | ||||
A | 45.2B | 6.7B | 36.57 | 6.71 | ||||
IDXX | 44.9B | 3.7B | 51.83 | 12.06 | ||||
DGX | 16.0B | 9.3B | 18.95 | 1.73 | ||||
NTRA | 13.1B | 1.2B | -35.76 | 10.81 | ||||
MEDP | 12.2B | 2.0B | 38.94 | 6.2 | ||||
CRL | 11.4B | 4.1B | 26.02 | 2.78 | ||||
EXAS | 9.3B | 2.5B | -38.69 | 3.67 | ||||
MID-CAP | ||||||||
GH | 3.1B | 603.7M | -6.73 | 5.14 | ||||
NEOG | 2.9B | 929.2M | 1.9K | 3.16 | ||||
SMALL-CAP | ||||||||
CDNA | 808.3M | 275.1M | -4.41 | 2.94 | ||||
ACRS | 84.8M | 31.1M | -1.1 | 2.73 | ||||
AWH | 33.0M | 9.2M | -2.24 | 3.6 | ||||
APDN | 2.5M | 5.5M | -0.2 | 0.45 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
bioAffinity Technologies, Inc. News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 |
Revenue | 8.7% | 2,406,391 | 2,213,356 | 298,484 | 19,738 | 13,542 | 7,346 | 1,150 | 1,306 |
Cost Of Revenue | - | - | - | 74,704 | 1,234 | 87.00 | - | 146 | 146 |
Gross Profit | - | - | - | 223,780 | 18,504 | 834 | - | 1,004 | 1,160 |
Operating Expenses | -6.0% | 4,351,621 | 4,631,786 | 2,518,284 | 1,796,854 | 1,558,804 | 1,626,379 | 977,160 | 685,279 |
S&GA Expenses | -0.3% | 2,185,944 | 2,192,328 | 2,023,917 | 1,426,469 | 1,169,559 | 1,133,756 | 595,702 | 408,620 |
R&D Expenses | -9.1% | 393,639 | 432,818 | 330,376 | 335,125 | 369,617 | 479,925 | 319,744 | 248,419 |
EBITDA Margin | 46.8% | -1.60 | -3.01 | -3.69 | -6.94 | -10.66 | -1,167 | - | - |
Interest Expenses | -7.0% | 23,550 | 25,325 | 8,785 | 1,360 | 1,655 | 89,290 | 896,502 | 399,265 |
Income Taxes | 60.1% | 3,672 | 2,293 | 2,294 | 4,587 | 11,819 | -1.00 | 300 | - |
Earnings Before Taxes | 17.4% | -1,958,143 | -2,370,871 | -2,288,590 | -1,735,586 | -1,520,971 | -1,674,583 | -4,919,158 | -88,052 |
EBT Margin | 45.9% | -1.69 | -3.13 | -3.80 | -7.76 | -12.88 | -1,697 | - | - |
Net Income | 17.3% | -1,961,815 | -2,373,164 | -2,290,884 | -1,740,173 | -1,532,790 | -1,674,583 | -4,919,458 | -88,052 |
Net Income Margin | 45.9% | -1.69 | -3.13 | -3.81 | -7.78 | -12.90 | -1,697 | - | - |
Free Cashflow | -48.9% | -2,387,362 | -1,602,861 | -1,532,682 | -1,363,810 | -1,561,355 | - | - | - |
Balance Sheet | |||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2021Q4 |
Assets | -2.1% | 8,049 | 8,222 | 10,189 | 8,873 | 10,465 | 12,182 | 14,063 | 1,453 |
Current Assets | -1.0% | 3,931 | 3,973 | 6,010 | 8,659 | 10,233 | 11,962 | 14,055 | 1,438 |
Cash Equivalents | -13.1% | 2,453 | 2,822 | 4,500 | 8,300 | 9,800 | 11,414 | 13,500 | 1,361 |
Inventory | -48.7% | 9.00 | 18.00 | 10.00 | 10.00 | 11.00 | 6.00 | 6.00 | - |
Net PPE | 0.6% | 461 | 459 | 512 | 207 | 225 | 214 | 2.00 | 5.00 |
Goodwill | 0% | 1,404 | 1,404 | 1,404 | - | - | - | - | - |
Liabilities | -17.1% | 2,792 | 3,366 | 3,196 | 775 | 796 | 1,139 | 1,464 | 13,200 |
Current Liabilities | -21.2% | 1,772 | 2,248 | 1,959 | 775 | 796 | 1,139 | 1,464 | 13,040 |
Shareholder's Equity | 8.3% | 5,257 | 4,855 | 6,994 | 8,098 | 9,668 | 11,043 | 12,599 | -15,790 |
Retained Earnings | -4.5% | -46,600 | -44,600 | -42,200 | -39,900 | -38,200 | -36,667 | -34,992 | -28,513 |
Additional Paid-In Capital | 4.8% | 51,745 | 49,394 | 49,161 | 47,979 | 47,809 | 47,652 | 47,533 | 12,704 |
Shares Outstanding | 22.6% | 11,514 | 9,395 | 9,217 | 8,478 | 8,463 | 8,381 | 4,204 | 2,677 |
Float | - | - | - | - | 14,000 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -45.1% | -2,345 | -1,616 | -1,532 | -1,359 | -1,529 | -1,300 | -1,760 | -376 | -633 | - | - |
Share Based Compensation | 21.0% | 284 | 235 | 186 | 170 | 158 | 37.00 | 79.00 | 27.00 | 106 | - | - |
Cashflow From Investing | -407.9% | -41.39 | 13.00 | -2,186 | -3.86 | -32.31 | - | - | - | - | - | - |
Cashflow From Financing | 2480.7% | 2,019 | -84.80 | -50.77 | -126 | -83.32 | -563 | 15,044 | -437 | 301 | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net Revenue | $ 2,406,391 | $ 921 |
Operating expenses: | ||
Direct costs and expenses | 1,573,441 | 87 |
Research and development | 393,639 | 369,617 |
Clinical development | 48,960 | 19,628 |
Selling, general and administrative | 2,185,944 | 1,147,875 |
Depreciation and amortization | 149,637 | 21,684 |
Total operating expenses | 4,351,621 | 1,558,891 |
Loss from operations | (1,945,230) | (1,557,970) |
Other income (expense): | ||
Interest income | 6,127 | 38,654 |
Interest expense | (23,550) | (1,655) |
Other expense | 4,510 | |
Total other expense | (12,913) | 36,999 |
Net loss before provision for income taxes | (1,958,143) | (1,520,971) |
Income tax expense | (3,672) | (11,819) |
Net loss | $ (1,961,815) | $ (1,532,790) |
Net loss per common share, basic | $ (0.20) | $ (0.18) |
Net loss per common share, diluted | $ (0.20) | $ (0.18) |
Weighted average common shares outstanding, basic | 9,915,426 | 8,433,689 |
Weighted average common shares outstanding, diluted | 9,915,426 | 8,433,689 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,453,165 | $ 2,821,570 |
Accounts and other receivables, net | 1,123,609 | 811,674 |
Inventory | 9,487 | 18,484 |
Prepaid expenses and other current assets | 344,900 | 321,017 |
Total current assets | 3,931,161 | 3,972,745 |
Non-current assets: | ||
Property and equipment, net | 461,209 | 458,633 |
Operating lease right-of-use asset, net | 347,860 | 370,312 |
Finance lease right-to-use, net | 1,069,601 | 1,165,844 |
Goodwill | 1,404,486 | 1,404,486 |
Intangible assets, net | 818,889 | 833,472 |
Other assets | 16,060 | 16,060 |
Total assets | 8,049,266 | 8,221,552 |
Current liabilities: | ||
Accounts payable | 383,993 | 604,789 |
Accrued expenses | 883,319 | 1,149,811 |
Unearned revenue | 30,174 | 33,058 |
Operating lease liability, current portion | 96,631 | 94,708 |
Finance lease liability, current portion | 372,787 | 365,463 |
Notes payable, current portion | 4,686 | |
Total current liabilities | 1,771,590 | 2,247,829 |
Non-current liabilities: | ||
Finance lease liability, net of current portion | 739,478 | 835,467 |
Operating lease liability, net of current portion | 258,110 | 283,001 |
Notes payable, net of current portion | 23,037 | |
Total liabilities | 2,792,215 | 3,366,297 |
Commitments and contingencies (See Note 11) | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2024, and December 31, 2023 | ||
Common stock, par value $0.007 per share; 25,000,000 shares authorized; 11,216,491 and 9,394,610 issued and outstanding at March 31, 2024, and at December 31, 2023, respectively. | 78,515 | 65,762 |
Additional paid-in capital | 51,744,830 | 49,393,972 |
Accumulated deficit | (46,566,294) | (44,604,479) |
Total stockholders’ equity | 5,257,051 | 4,855,255 |
Total liabilities and stockholders’ equity | $ 8,049,266 | $ 8,221,552 |